PepGen approved to initiate first-in-human trials of PGN-EDO51

In December 2020, CureDuchenne Ventures announced funding support for PepGen, Inc. to advance their Duchenne exon-skipping program to the clinic for trial. PepGen’s EDO cell-penetrating peptide platform is designed to improve the delivery of therapeutic oligonucleotides to affected muscle tissue, increase the efficiency of exon-skipping, and address the fundamental cause of Duchenne muscular dystrophy.

In today’s press release, PepGen announced that their application to initiate a first-in-human clinical study of their lead Enhanced Delivery Oligonucleotide (EDO) candidate, PGN-EDO51, was approved by Health Canada!

The unique potential of this platform to reach all the tissues affected by Duchenne and especially cardiac tissue, is significant. Heart disease is a key cause of morbidity and mortality in Duchenne and a central focus of ours to help improve and extend the lives of those living with the disease. CureDuchenne is thrilled to see our support goals realized and congratulates PepGen on the upcoming initiation of their first-in-human study with PGN-ED051.

You can read PepGen’s full press release here: https://pepgen.com/2022/03/15/pepgen-announces-approval-of-cta-to-begin-first-in-human-trials-of-pgn-edo51-to-treat-duchenne-muscular-dystrophy/